Johannes Textor, theme Cancer development and immune defense, has been awarded a program grant of 1 million US dollars by The Human Frontier Science Program (HFSP), together with his team members Judith Mandl (McGill University, Montreal, Canada) and Daniel Parisi (Buenos Aires institute of Technology, Argentina).
The T cells of the adaptive immune system are constantly on the move, can enter most tissues, and operate inlarge crowds. Millions of densely packed T cells roam the lymphatic organs in search of foreign antigen while activated T cells divide vigorously and flock to tissues where they mount local immune responses to pathogens or cancer cells.
The HFSP project combines expertise in immunology, computational biology, and pedestrian dynamics to shed light how T cell crowds remain motile with such remarkable efficiency in many conditions and what it would take to disrupt their smooth flow
HFSP grants are highly competitive awards intended for basic research at the frontier of human knowledge. They are open to applicants from all nations, and awardees are selected through a rigorous year-long review process. From more than 700 proposals that were initially submitted by scientists based in more than 50 different countries, only the top 4% were funded, and Johannes Textor's propasal was ranked third overall. Johannes Textor was the only scientist from a Dutch instutition to be selected.
Related news items
Evaluation of an AI system for detection of COVID-19 on Chest X-Ray images22 May 2020
In the journal Radiology RIHS researcher Keelin Murphy described how an artificial intelligence system (CAD4COVID-XRay) can identify characteristics of COVID-19 on chest x-rays with performance comparable to six independent radiologists.read more
First clinical trial with genetically modified malaria vaccine completed22 May 2020
In an innovative study, Radboudumc and LUMC jointly tested a candidate vaccine based on a genetically weakened malaria parasite. The results of this clinical trial, published in Science Translational Medicine, show that the vaccine is safe and elicits a defense response against a malaria infection.read more
New step in the development of a vaccine against malaria22 May 2020
A new vaccine based on rodent malaria parasites achieved a 95% reduction in infection of the liver in humans. An international consortium publishes the results in Science Translational Medicine.read more
Retirement of RIMLS Laboratory Assistant Nelly Mulders-Langen19 May 2020
After more than 45 years, Nelly said goodbye to "her" Radboudumc. We are going to miss her dedication and collegiality, but we wish her al the best for the future in good health.read more